Peptide Encyclopedia / PE-22-28
EncyclopediaPE-22-28 is a synthetic analog of spadin, derived from the sortilin propeptide, designed to block TREK-1 potassium channels for antidepressant-like and neuroplasticity effects. The research sits in rodent models, no human trials have finished, and it sells as a research chemical only. Educational only, not medical advice.
| Category | Cognitive |
| Regulatory status | Not FDA-approved; research chemical only. |
A synthetic peptide derived from the sortilin propeptide and analog of spadin, proposed to block TREK-1 (TWIK-related potassium) channels, an action investigated for rapid antidepressant-like and neuroplasticity effects. Mechanism is based largely on preclinical models.
uncertain; no rigorous human pharmacokinetic data (spadin itself is short-lived, motivating analogs like PE-22-28). Commonly reported use/dosing: No validated human protocol. Sold as a research chemical; any reported low-microgram subcutaneous/intranasal use is anecdotal, not a clinically established regimen.
Not FDA-approved; research chemical only. Not a recognized therapeutic; human safety/efficacy not established and gray-market sourcing is common.
Human safety data essentially absent. Unknown long-term effects; research-grade products carry purity/contamination risk. Use is experimental and not advised outside formal research.
Preclinical (rodent) research on depression/neurogenesis; no completed human clinical trials.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. PE-22-28 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
